Nicotinamide riboside

烟酰胺核糖

Report date: 2026/05/20 20:02:01

Base Information

Drug NameNicotinamide riboside
Drug Alias NameNicotinamide ribonucelosideNiagen
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionNAD-dependent protein deacetylase sirtuin-5 inhibitors
TargetsNAD-dependent protein deacetylase sirtuin-5
Therapy Area/IndicationsDiabetic peripheral neuropathyCoronavirus Disease 2019 (COVID-19)Cognitive Dysfunction +[19] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesNetherlandsNorway
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesChromadexNational Institutes Of Health
China Registration ClassN/A

Develop Information

Active CompaniesChromadex IncNiagen Bioscience IncUT Health San Antonio +[11] 
Inactive CompaniesRadboud University Medical CenterUniversity Of Maryland, BaltimoreUniversity Of Colorado Boulder
Active IndicationsCoronavirus Disease 2019 (COVID-19)Cognitive DysfunctionCognition Disorders +[16] 
Inactive IndicationsDiabetic peripheral neuropathyHealthy AgingHeart Failure, Systolic

Other Information

ATC CodeA11HA01
Related LinksWikipedia